PCI Biotech Holding ASA (OSL:PCIB) Total Assets: kr18.52 Mil (As of Jun. 2025)


OSL:PCIB PCI Biotech Holding ASA OSL:PCIB
6 GF Score
Price kr0.12
! 1 Warning Sign
View Full Analysis

What is PCI Biotech Holding ASA Total Assets?

PCI Biotech Holding ASA OSL:PCIB -12.21% 6 Total Assets is kr18.52 Mil as of Jun. 2025. GuruFocus rates OSL:PCIB with a GF Score™ of 6/100. The stock has 1 warning sign investors should review.

PCI Biotech Holding ASA's Total Assets for the quarter that ended in Jun. 2025 was kr18.52 Mil.

During the past 12 months, PCI Biotech Holding ASA's average Total Assets Growth Rate was -28.70% per year. During the past 3 years, the average Total Assets Growth Rate was -39.90% per year. During the past 5 years, the average Total Assets Growth Rate was -34.20% per year. During the past 10 years, the average Total Assets Growth Rate was -1.70% per year.

During the past 13 years, PCI Biotech Holding ASA's highest 3-Year average Total Assets Growth Rate was 38.60%. The lowest was -47.10%. And the median was 8.70%.

Total Assets is connected with ROA %. PCI Biotech Holding ASA's annualized ROA % for the quarter that ended in Jun. 2025 was -92.67%. Total Assets is also linked to Revenue through Asset Turnover. PCI Biotech Holding ASA's Asset Turnover for the quarter that ended in Jun. 2025 was 0.00.

PCI Biotech Holding ASA  (OSL:PCIB) Total Assets Explanation

Total Assets is connected with ROA %.

PCI Biotech Holding ASA's annualized ROA % for the quarter that ended in Jun. 2025 is

ROA %=Net Income (Q: Jun. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Jun. 2025 ))/ count )
=-23.046/( (31.215+18.523)/ 2 )
=-23.046/24.869
=-92.67 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

PCI Biotech Holding ASA's Asset Turnover for the quarter that ended in Jun. 2025 is

Asset Turnover
=Revenue (Q: Jun. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Jun. 2025 ))/ count )
=0/( (31.215+18.523)/ 2 )
=0/24.869
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

PCI Biotech Holding ASA Total Assets Related Terms

PCI Biotech Holding ASA Total Assets Historical Data

* Premium members only.

The historical data trend for PCI Biotech Holding ASA's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PCI Biotech Holding ASA Total Assets Chart

PCI Biotech Holding ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 209.12 135.98 63.48 44.05 31.22

PCI Biotech Holding ASA Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 52.52 44.05 37.41 31.22 18.52
OSL:PCIB
6GF Score
PCI Biotech Holding ASA OSL:PCIB
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PCI Biotech Holding ASA Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

PCI Biotech Holding ASA's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets=Total Equity (A: Dec. 2024 )+Total Liabilities (A: Dec. 2024 )
=23.453+7.762
=31.22

PCI Biotech Holding ASA's Total Assets for the quarter that ended in Jun. 2025 is calculated as

Total Assets=Total Equity (Q: Jun. 2025 )+Total Liabilities (Q: Jun. 2025 )
=12.515+6.008
=18.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of kr18.52 Mil mean?
PCI Biotech Holding ASA (OSL:PCIB) has a Total Assets of kr18.52 Mil as of Jun. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on PCI Biotech Holding ASA and its competitors.
Is PCI Biotech Holding ASA's Total Assets too high?
PCI Biotech Holding ASA's current Total Assets is kr18.52 Mil. Overall, PCI Biotech Holding ASA has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does PCI Biotech Holding ASA's Total Assets compare to VRTX and REGN?
PCI Biotech Holding ASA's Total Assets of kr18.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on PCI Biotech Holding ASA and its competitors. PCI Biotech Holding ASA's current Total Assets is kr18.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PCI Biotech Holding ASA stock overvalued right now?
PCI Biotech Holding ASA (OSL:PCIB) has a current Total Assets of kr18.52 Mil. The current Total Assets is kr18.52 Mil. PCI Biotech Holding ASA's overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For PCI Biotech Holding ASA (OSL:PCIB), the current Total Assets is kr18.52 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PCI Biotech Holding ASA Business Description

Address Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.
6GF Score

Get the complete analysis for OSL:PCIB

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.12
Price